Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in a ...

Anti-TNF monotherapy Increased efficacy (compared to immunomodulators) Loss of response, immunogenicity Long-term combination therapy(e.g., azathioprine with infliximab) Increased efficacy (compared ...

Use of lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) to predict relapse in patients with diffuse large B-cell lymphoma (DLBCL). Background: Inflammatory bowel disease ...

Expert Rev Clin Immunol. 2013;9(2):117-127. Anti-TNF monotherapy Increased efficacy (compared to immunomodulators) Loss of response, immunogenicity Long-term combination therapy(e.g., azathioprine ...

In a propensity score-matched analysis including 754 patients ages 50 and up, use of vedolizumab was associated with a 45.4% risk of treatment failure -- defined as a composite risk of IBD-related ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Vedolizumab and ustekinumab associated with a lower risk for infection-related hospitalizations ...

Patients with Crohn's disease or ulcerative colitis (collectively referred to as inflammatory bowel disease [IBD]) regularly receive treatment with thiopurine drugs to maintain remission. But an ...

Patients with rheumatoid arthritis (RA) who used tumor necrosis factor (TNF) inhibitors had significantly higher rates of nonmelanoma skin cancer and non-Hodgkin lymphoma. A new report based on ...

Please provide your email address to receive an email when new articles are posted on . Mirikizumab, a monoclonal antibody poised to become first-in-class treatment for ulcerative colitis, has the ...

A large study examining major congenital malformations following in utero exposure to thiopurines or tumor necrosis factor ...